LeadIQ logo
Learn more at LeadIQ.com

Insights

Partnership Opportunities Touchlight Genetics has established partnership agreements with renowned institutions like the University of Nottingham and University of Liverpool for the development of DNA vaccines targeting Zika virus and neoantigen vaccines for non-small cell lung cancer patients. These collaborations present potential sales opportunities for Touchlight in providing enzymatic DNA technology and manufacturing services to support these cutting-edge research projects.

Expansion into New Markets Touchlight's partnership with Curia and the integration of its dbDNA platform with Curia's mRNA manufacturing capability demonstrate the company's strategic expansion into new markets. Sales representatives can explore opportunities to offer combined solutions to pharmaceutical and biotech companies seeking rapid, reliable, and high-quality genetic medicine development services.

Product Portfolio Diversification Touchlight Genetics' launch of Discovery grade dbDNA expands its service offerings to support customer candidate screening. Sales development representatives can capitalize on this new product launch by targeting companies in need of specialized synthetic DNA solutions for early-stage drug discovery and development, positioning Touchlight as a key partner in advancing their research pipelines.

Key Leadership Appointment The appointment of Dr. Verna McErlane as the SVP and Global Head of Sales at Touchlight Genetics indicates a strategic focus on driving sales growth and expanding market reach. Sales teams can leverage Dr. McErlane's expertise to strengthen client relationships, drive new business opportunities, and enhance the company's competitive positioning in the biotechnology research industry.

Competitive Differentiation Touchlight's innovative enzymatic DNA technology and proprietary manufacturing process differentiate it from competitors in the market. Sales professionals can leverage this unique selling point to highlight the scalability, speed, and purity of Touchlight's synthetic DNA solutions, positioning the company as a preferred partner for biotech and pharmaceutical companies seeking advanced genetic medicine production capabilities.

Similar companies to Touchlight

Touchlight Tech Stack

Touchlight uses 8 technology products and services including MySQL, Google Font API, React, and more. Explore Touchlight's tech stack below.

  • MySQL
    Database
  • Google Font API
    Font Scripts
  • React
    Javascript Frameworks
  • AOS
    Javascript Libraries
  • Google Tag Manager
    Tag Management
  • Nginx
    Web Servers
  • Apache
    Web Servers
  • Twitter
    Widgets

Media & News

Touchlight's Email Address Formats

Touchlight uses at least 1 format(s):
Touchlight Email FormatsExamplePercentage
First.Last@touchlight.comJohn.Doe@touchlight.com
48%
Last@touchlight.comDoe@touchlight.com
2%
FL@touchlight.comJD@touchlight.com
2%
First.Last@touchlight.comJohn.Doe@touchlight.com
48%

Frequently Asked Questions

Where is Touchlight's headquarters located?

Minus sign iconPlus sign icon
Touchlight's main headquarters is located at Hampton, London, England TW12 2ER GB. The company has employees across 6 continents, including EuropeNorth AmericaAfrica.

What is Touchlight's official website and social media links?

Minus sign iconPlus sign icon
Touchlight's official website is touchlight.com and has social profiles on LinkedIn.

How much revenue does Touchlight generate?

Minus sign iconPlus sign icon
As of September 2024, Touchlight's annual revenue reached $35M.

What is Touchlight's SIC code NAICS code?

Minus sign iconPlus sign icon
Touchlight's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Touchlight have currently?

Minus sign iconPlus sign icon
As of September 2024, Touchlight has approximately 162 employees across 6 continents, including EuropeNorth AmericaAfrica. Key team members include Chief Executive Officer: K. F.Chief Business Officer: T. D.Chief Financial Officer: A. H.. Explore Touchlight's employee directory with LeadIQ.

What industry does Touchlight belong to?

Minus sign iconPlus sign icon
Touchlight operates in the Biotechnology Research industry.

What technology does Touchlight use?

Minus sign iconPlus sign icon
Touchlight's tech stack includes MySQLGoogle Font APIReactAOSGoogle Tag ManagerNginxApacheTwitter.

What is Touchlight's email format?

Minus sign iconPlus sign icon
Touchlight's email format typically follows the pattern of . Find more Touchlight email formats with LeadIQ.

How much funding has Touchlight raised to date?

Minus sign iconPlus sign icon
As of September 2024, Touchlight has raised $2.4M in funding. The last funding round occurred on Nov 28, 2022 for $2.4M.

When was Touchlight founded?

Minus sign iconPlus sign icon
Touchlight was founded in 2008.
Touchlight

Touchlight

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Touchlight is an innovation-driven leading CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing already accepted in 2022, our enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and in vivo gene editing innovation. With multiple client products already in the clinic, our evidence-based, data-supported synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. Our company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, our team is inspired by breakthroughs in genome sequencing, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies. 

To address these challenges, we developed our first novel synthetic DNA vector, dbDNA™, alongside a proprietary enzymatic manufacturing process. This groundbreaking approach enables the production of complex DNA sequences with remarkable speed, scale, and purity, surpassing the limitations of traditional pDNA production while transforming the economics of bringing these therapies to market more efficiently and sustainably. Touchlight’s commitment to innovation is continually fueling product improvements and new product development. As of early 2024, we have partnered with hundreds of biotech and top 10 pharmaceutical companies, producing synthetic DNA for use as both a starting material and an active pharmaceutical ingredient. By the end of this year, dbDNA™ will be one of multiple synthetic DNA products in our portfolio that will continue to pave the way for more accessible cell and gene therapies. 

Section iconCompany Overview

Headquarters
Hampton, London, England TW12 2ER GB
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
51-200

Section iconFunding & Financials

  • $2.4M

    Touchlight has raised a total of $2.4M of funding over 10 rounds. Their latest funding round was raised on Nov 28, 2022 in the amount of $2.4M.

  • $10M$50M

    Touchlight's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $2.4M

    Touchlight has raised a total of $2.4M of funding over 10 rounds. Their latest funding round was raised on Nov 28, 2022 in the amount of $2.4M.

  • $10M$50M

    Touchlight's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.